-
Eli Lilly Full Year 2025 Financial Report
Eli Lilly
Eli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
-
Eli Lilly 2025 H1 Report
Financial statements
Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
-
-
-
-
Pharma's $158B U.S. Manufacturing Surge
Market Trend
Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
元朗区|
太仆寺旗|
迁安市|
桃园县|
自治县|
句容市|
黄大仙区|
汝阳县|
凤山市|
望江县|
丘北县|
抚松县|
天等县|
体育|
万载县|
广南县|
霸州市|
孟州市|
榆中县|
泽州县|
缙云县|
桂阳县|
镇坪县|
辽中县|
惠安县|
五华县|
从江县|
昔阳县|
乌拉特中旗|
西贡区|
手机|
洪洞县|
和龙市|
肥城市|
罗田县|
马尔康县|
西宁市|
尼勒克县|
安国市|
宁武县|
耿马|